Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2022 | TKI-related toxicities in CML & the importance of long-term monitoring

Giuseppe Saglio • 28 Sep 2022
SOHO 2022
Chronic Myeloid Leukemia Leukemia

Giuseppe Saglio, MD, University of Turin, Turin, Italy, discusses toxicities associated with tyrosine kinase inhibitor (TKI) treatment in patients with chronic myeloid leukemia (CML), drawing focus on the importance of monitoring these patients in the long-term, and commenting on the financial toxicity of treatment in CML. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Giuseppe Saglio

2:26
An insight into the aims of the Eurasian Hematology-Oncology Group
Giuseppe Saglio • 25 Oct 2022
3:20
The current standard of care in CML and insights into the use of first- and second-generation TKIs
Giuseppe Saglio • 25 Oct 2022
2:11
Addressing the issue of resistance to TKIs in CML
Giuseppe Saglio • 28 Oct 2022
2:36
Is it possible to achieve TFR with low-dose TKI therapy?
Giuseppe Saglio • 22 Oct 2022

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals